Study guide
12.3 Antibiotic Classes, Intrinsic Resistance, and Genetic Markers
ASCP Microbiology Technologist M ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current M(ASCP) Exam Facts 1.2 CAT, Scoring, Retakes, and CMP 1.3 Eligibility Routes and Clinical Experience
2 Preanalytic: Collection and Transport
2.1 Patient Identification and Specimen Labeling 2.2 Specimen Collection, Sterile Technique, and Blood Cultures 2.3 Transport Devices, Atmosphere, Time, and Temperature
3 Preanalytic: Processing, Media, and Incubation
3.1 Prioritization, Rejection, and Specimen Preparation 3.2 Media Types, Components, and Selection 3.3 Inoculation, Incubation Conditions, and Slide Preparation
4 Preanalytic: Stains
4.1 Gram Stain: Procedure, Principle, and Interpretation 4.2 Acid-Fast and Modified Acid-Fast Stains 4.3 KOH, Calcofluor-White, Trichrome, Giemsa, and Acridine Orange
5 Bacteriology: Blood and Bone Marrow
5.1 Blood Culture Systems and Rapid Identification 5.2 Bloodstream Pathogens and Skin Flora Significance 5.3 Endocarditis, Bone Marrow Pathogens, and Pathogenicity
6 Bacteriology: CSF and Sterile Body Fluids
6.1 CSF Sources and Acute Meningitis Pathogens 6.2 Shunt Infections, CSF Correlates, Antigen and Molecular Methods 6.3 Sterile Body Fluids: Pathogens, Flora, and Molecular Methods
7 Bacteriology: Respiratory Tract
7.1 Lower Respiratory Specimens, CAP, and HAP Pathogens 7.2 Cystic Fibrosis Pathogens and Quantitative Reporting 7.3 Upper Respiratory: Pharyngitis, Otitis, Sinusitis, Antigen/Molecular
8 Bacteriology: Gastrointestinal Tract
8.1 Enteric Pathogens: Culture and Colony Morphology 8.2 Clostridioides difficile, Shiga Toxin, and Serotyping 8.3 Helicobacter pylori Detection and GI Pathogenicity
9 Bacteriology: Skin, Soft Tissue, and Bone
9.1 Skin, Soft Tissue, and Bone Pathogens 9.2 Bite Wounds and Zoonotic Infections 9.3 SST Pathogenicity and Virulence Mechanisms
10 Bacteriology: Genital Tract and Urine
10.1 Genital Flora and Vaginitis Pathogens 10.2 Neisseria gonorrhoeae, Chlamydia trachomatis, GBS, and Mycoplasma 10.3 Urinary Pathogens, Colony Counts, and Urinalysis Correlation
11 Bacteriology: Identification Methods
11.1 Colony Morphology and Rapid Presumptive Tests 11.2 Conventional Biochemicals and Commercial Kits 11.3 Automated Methods, MALDI-TOF MS, Molecular, and 16S Sequencing
12 Bacteriology: Antimicrobial Susceptibility and Resistance
12.1 Microbroth Dilution, Disk Diffusion, and Gradient Diffusion 12.2 Phenotypic Detection of Resistance 12.3 Antibiotic Classes, Intrinsic Resistance, and Genetic Markers
13 Bacteriology: Resistance Screening and Select Agents
13.1 MRSA/MSSA, VRE, ESBL/CRE Screening 13.2 BSL-3 Pathogens and Select-Agent Presumptive Identification 13.3 Laboratory Response Network and Select-Agent Pathogenicity
14 Mycobacteriology and Nocardia
14.1 Specimens, Major Pathogens, and Disease States 14.2 Acid-Fast Reaction, Colony Morphology, and Growth Characteristics 14.3 Identification Methods, Direct Molecular Detection, and TB Therapy
15 Virology
15.1 Respiratory, Vesicle, Meningitis, and GI Viruses 15.2 Hepatitis, HIV, and Immunocompromised-Host Viruses 15.3 Direct Detection Methods and HPV Cervical Screening
16 Parasitology
16.1 Blood, Tissue, and Brain Protozoa 16.2 Intestinal/Urogenital Protozoa and Helminths 16.3 Microscopy, Antigen/Molecular Detection, Insects and Arthropods
17 Mycology
17.1 Yeasts: Candida, Cryptococcus, and Malassezia 17.2 Dimorphic Fungi and Dermatophytes 17.3 Mucorales, Hyaline Molds, Pneumocystis, and Identification Methods
18 Serology
18.1 Immunoglobulin Response and Antigen-Antibody Methods 18.2 Viral Serodiagnosis: Hepatitis, EBV, HIV, CMV, Rubella, Measles 18.3 Treponema, Borrelia, and TB Infection Serodiagnosis
19 Laboratory Operations: Postanalytic Procedures and Quality
19.1 Documentation, Critical Values, Corrected Reports, and Public Health 19.2 Quality Control, Root-Cause Analysis, and POCT 19.3 Proficiency Testing, Competency, and Accreditation
20 Laboratory Operations: Safety, Mathematics, and Instrumentation
20.1 Biosafety, PPE, Bloodborne Pathogens, and SDS 20.2 Emergencies and Packaging/Transportation of Specimens 20.3 Laboratory Mathematics and Instrumentation
12.3 Antibiotic Classes, Intrinsic Resistance, and Genetic Markers
Key Takeaways Explain This Topic AI
Map class to target: beta-lactams bind PBPs; glycopeptides bind D-Ala-D-Ala; aminoglycosides and tetracyclines hit 30S; macrolides/lincosamides hit 50S; fluoroquinolones hit DNA gyrase/topoisomerase IV; TMP-SMX blocks folate; metronidazole damages DNA in anaerobes.
mecA encodes PBP2a and equals oxacillin/cefoxitin resistance; vanA rebuilds D-Ala-D-Lac and equals high-level vancomycin resistance; blaKPC is a serine carbapenemase (CRE).
Intrinsic patterns to reject as ID/method errors: Klebsiella ampicillin; Proteus nitrofurantoin and tetracycline; P. aeruginosa many non-antipseudomonal agents; Stenotrophomonas carbapenems (L1 metallo); Enterococcus cephalosporins and aminoglycoside monotherapy; anaerobes aminoglycosides.
Genotype must match the report: mecA-positive staphylococci are oxacillin/cefoxitin-resistant even if a misleading oxacillin disk looks large.
Last updated: August 2026
Once you can generate an MIC or a zone, the exam asks whether the result is biologically plausible. Official outline II.K pairs major antibiotic classes and their targets with intrinsic resistance patterns and with the genetic markers mecA , vanA , and blaKPC . A marker is not trivia; it rewrites the report. Cascade lists of which drugs to report by body site remain SM-only and are not M-tested.
Mechanisms of action: one target per class
Class Primary target High-yield consequence
Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) Penicillin-binding proteins (PBPs); block peptidoglycan transpeptidation Cell-wall lysis in growing cells; fails if PBP is altered (PBP2a, pneumococcal PBPs) or an enzyme opens the ring
Glycopeptides (vancomycin) Bind D-Ala-D-Ala termini and sterically block cross-linking Too large to pass the Gram-negative outer membrane; defeated when ligase makes D-Ala-D-Lac ( vanA )
Aminoglycosides 30S ribosomal subunit; mRNA misreading Need oxygen-dependent uptake — intrinsically inactive vs anaerobes; enterococcal synergy only if high-level resistance is absent
Macrolides and lincosamides 50S ribosomal subunit erm methylation or efflux; the D-test is this biochemistry on a plate
- Fluoroquinolones DNA gyrase (GyrA) and topoisomerase IV (ParC) Stepwise QRDR mutations; not a cell-wall class
- Tetracyclines 30S ; block aminoacyl-tRNA docking Intrinsic resistance in Proteus ; efflux common
Trimethoprim–sulfamethoxazole Sequential folate synthesis (DHPS then DHFR) Antagonized by thymidine in agar (method trap); enterococci can use exogenous folate in vivo
Metronidazole Reduced to DNA-damaging radicals only in a low-redox (anaerobic) cytoplasm Active vs many Gram-negative anaerobes; not 30S “aminoglycoside-like” action and not useful for facultative aerobes
Beta-lactams are PBP drugs. Carbapenems are still beta-lactams; KPC is a beta-lactamase , not a ribosomal enzyme. Vancomycin is not a beta-lactam and does not bind PBPs — it ties up the stem peptide. That distinction is how you avoid answering “ mecA makes vancomycin R.”
Genetic markers: mecA , vanA , blaKPC
mecA lives on a staphylococcal cassette chromosome (SCCmec) and encodes PBP2a . Beta-lactams that rely on native PBPs no longer bind efficiently, so the isolate is oxacillin-resistant and, by the CLSI surrogate, cefoxitin-resistant. Phenotype = MRSA (or methicillin-resistant coagulase-negative staphylococci if the species is not S. aureus ). Correlate: mecA detected → report oxacillin/cefoxitin resistant ; do not leave oxacillin susceptible because a mis-set oxacillin disk looked large. mecA does not confer vancomycin resistance.
vanA encodes a ligase that rebuilds peptidoglycan precursors with D-Ala-D-Lac , which vancomycin binds about a thousand-fold less well. Phenotype = high-level vancomycin resistance, typically with teicoplanin resistance, in E. faecium / E. faecalis (VRE). vanA is often plasmid-borne and transferable, unlike intrinsic vanC . Correlate: vanA → vancomycin resistant ; a vanA PCR on an E. faecium blood isolate is incompatible with a vancomycin-susceptible report.
blaKPC encodes Klebsiella pneumoniae carbapenemase, a class A serine enzyme that hydrolyzes carbapenems and other beta-lactams. Phenotype = meropenem/imipenem/ertapenem resistance or an elevated MIC in Enterobacterales (CRE when definitions are met). mCIM-positive and eCIM-negative fits a serine enzyme such as KPC; a validated molecular panel names blaKPC . EDTA does not rescue KPC. Correlate: blaKPC → do not report carbapenems susceptible.
Intrinsic resistance patterns (organism biology, not body-site cascade)
These chromosomal, expected resistances should make you reject a “fully susceptible” panel as a method or identification error.
Klebsiella pneumoniae / K. oxytoca : intrinsic ampicillin (and amoxicillin) resistance from chromosomal penicillinase (SHV-type in K. pneumoniae ). An ampicillin-susceptible Klebsiella is a red flag for misidentification or a failed well. That does not automatically make every cephalosporin intrinsically resistant.
Proteus spp. (especially P. mirabilis ): intrinsic resistance to nitrofurantoin and tetracycline (and polymyxins/colistin). Do not release nitrofurantoin as a urinary option for Proteus because a well was empty. Swarming is not a susceptibility result.
Pseudomonas aeruginosa : a long intrinsic list driven by impermeability, efflux, and chromosomal AmpC — ampicillin, cefazolin, ceftriaxone, ertapenem, tetracycline, tigecycline, TMP-SMX, and other agents that never were antipseudomonal. The drugs you actually test are antipseudomonal (piperacillin, ceftazidime, cefepime, meropenem, aminoglycosides, ciprofloxacin). A Pseudomonas reported ampicillin-S is wrong.
Stenotrophomonas maltophilia : intrinsic carbapenem resistance from L1 metallo-beta-lactamase (zinc enzyme), plus an L2 cephalosporinase. Meropenem “S” on a Stenotrophomonas panel is a method/ID error. TMP-SMX is the historical drug of choice; that is a therapeutic association, not an SM-only site cascade.
Enterococcus spp.: intrinsic resistance to cephalosporins (low-affinity PBPs) and to clinically useful aminoglycoside monotherapy because of poor uptake. High-level aminoglycoside resistance testing (gentamicin and streptomycin) is done only to predict synergy with a cell-wall agent, not because gentamicin is a stand-alone enterococcal drug. TMP-SMX may look active in vitro but fails in vivo because enterococci use exogenous folate. E. faecium is often ampicillin-resistant; E. faecalis is usually ampicillin-susceptible — use that split as an identity check.
Anaerobes: aminoglycosides require oxygen-dependent electron-transport uptake, so Bacteroides , Clostridium , and related anaerobes are intrinsically aminoglycoside-resistant. Metronidazole, not gentamicin, is the anaerobic DNA-damage agent. Some Gram-positive anaerobes ( Actinomyces , Cutibacterium ) are metronidazole-resistant; that is species biology, not a reason to add gentamicin to the anaerobic panel.
Genotype–phenotype correlation as a reporting check
If molecular and phenotypic AST disagree, troubleshoot before release:
mecA or PBP2a positive, cefoxitin screen negative → repeat both; do not report oxacillin-S.
vanA positive, vancomycin MIC in the susceptible range → repeat identification and MIC; mixed culture or PCR contamination is more likely than new biology.
blaKPC positive, meropenem clearly wild-type susceptible → confirm mix and the carbapenemase assay; a true KPC producer should not look like wild-type E. coli .
Phenotype can also exist without that named gene: BORSA without mecA , vanB instead of vanA , NDM instead of KPC. The outline names mecA , vanA , and blaKPC because they are the highest-yield correlates, not because they are the only alleles on earth.
Work ASCP M practice questions on intrinsic-resistance mismatches (ampicillin-S Klebsiella , meropenem-S Stenotrophomonas ) and on mecA / vanA / blaKPC report edits.